Plus Therapeutics (PSTV) Competitors $1.20 +0.01 (+0.84%) (As of 11:48 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PSTV vs. IDXG, DRIO, STIM, NXGL, FEMY, NRXS, MDAI, MHUA, IINN, and LFWDShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Interpace Biosciences (IDXG), DarioHealth (DRIO), Neuronetics (STIM), NEXGEL (NXGL), Femasys (FEMY), NeurAxis (NRXS), Spectral AI (MDAI), Meihua International Medical Technologies (MHUA), Inspira Technologies Oxy B.H.N. (IINN), and ReWalk Robotics (LFWD). Plus Therapeutics vs. Interpace Biosciences DarioHealth Neuronetics NEXGEL Femasys NeurAxis Spectral AI Meihua International Medical Technologies Inspira Technologies Oxy B.H.N. ReWalk Robotics Interpace Biosciences (NASDAQ:IDXG) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has preferable valuation and earnings, IDXG or PSTV? Interpace Biosciences has higher revenue and earnings than Plus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterpace Biosciences$40.21M0.29$800KN/AN/APlus Therapeutics$4.91M1.44-$13.32M-$2.53-0.47 Does the media prefer IDXG or PSTV? In the previous week, Plus Therapeutics had 15 more articles in the media than Interpace Biosciences. MarketBeat recorded 15 mentions for Plus Therapeutics and 0 mentions for Interpace Biosciences. Plus Therapeutics' average media sentiment score of 0.55 beat Interpace Biosciences' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Interpace Biosciences Neutral Plus Therapeutics Positive Which has more volatility & risk, IDXG or PSTV? Interpace Biosciences has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Is IDXG or PSTV more profitable? Interpace Biosciences has a net margin of 10.39% compared to Plus Therapeutics' net margin of -225.07%. Plus Therapeutics' return on equity of 0.00% beat Interpace Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Interpace Biosciences10.39% -8.09% 37.14% Plus Therapeutics -225.07%N/A -154.56% Does the MarketBeat Community prefer IDXG or PSTV? Interpace Biosciences received 253 more outperform votes than Plus Therapeutics when rated by MarketBeat users. Likewise, 72.83% of users gave Interpace Biosciences an outperform vote while only 61.68% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformInterpace BiosciencesOutperform Votes31972.83% Underperform Votes11927.17% Plus TherapeuticsOutperform Votes6661.68% Underperform Votes4138.32% Do institutionals and insiders hold more shares of IDXG or PSTV? 5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by company insiders. Comparatively, 5.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate IDXG or PSTV? Plus Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 1,066.67%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Interpace Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Interpace Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryInterpace Biosciences and Plus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.08M$4.47B$5.09B$8.79BDividend YieldN/A36.79%5.04%4.07%P/E Ratio-0.4714.1093.0914.02Price / Sales1.4444.061,220.6787.41Price / CashN/A52.2739.4936.27Price / Book-1.365.786.936.33Net Income-$13.32M$13.76M$118.83M$225.71M7 Day Performance-4.76%-0.67%-1.74%-0.58%1 Month Performance-14.29%0.90%-3.60%1.49%1 Year Performance-34.43%51.59%31.91%27.23% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics3.2264 of 5 stars$1.20+0.8%$14.00+1,066.7%-37.4%$7.08M$4.91M-0.4720Analyst RevisionGap UpIDXGInterpace BiosciencesN/A$2.68+0.4%N/A+135.6%$11.79M$40.21M0.00152Gap DownDRIODarioHealth1.8695 of 5 stars$0.82+5.4%$4.00+386.5%-31.6%$28.04M$20.35M-0.93200Gap UpSTIMNeuronetics2.3981 of 5 stars$0.81+0.9%$4.67+476.1%-40.6%$24.58M$71.35M0.00180NXGLNEXGEL1.4395 of 5 stars$3.30flatN/A+84.4%$22.41M$4.09M0.0010FEMYFemasys2.4841 of 5 stars$0.97-0.5%$10.00+928.3%+2.8%$22.27M$1.07M0.0030Analyst RevisionNRXSNeurAxisN/A$3.15-1.3%N/A+35.9%$21.99M$2.46M0.0019MDAISpectral AI2.5746 of 5 stars$1.09+2.8%$4.50+312.8%-59.4%$20.26M$18.06M0.0078MHUAMeihua International Medical Technologies0.3475 of 5 stars$0.71+9.4%N/A-66.4%$17.81M$97.10M0.00620Gap UpIINNInspira Technologies Oxy B.H.N.0.3151 of 5 stars$1.36+3.0%N/A+11.3%$17.16MN/A0.0020News CoverageGap UpLFWDReWalk Robotics3.5648 of 5 stars$1.86+0.5%$13.00+598.9%N/A$16.39M$13.85M-0.7460 Related Companies and Tools Related Companies Interpace Biosciences Competitors DarioHealth Competitors Neuronetics Competitors NEXGEL Competitors Femasys Competitors NeurAxis Competitors Spectral AI Competitors Meihua International Medical Technologies Competitors Inspira Technologies Oxy B.H.N. Competitors ReWalk Robotics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PSTV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
